CVM FOIA Electronic Reading Room
Policy Statements
Administrative Staff Manuals
Product Approval Information
- Freedom of Information (FOI) Summaries for Approved and Conditionally Approved Animal Drugs
- Veterinary Master Files
- Environmental Impact Considerations
- NSAID Labels
- Method of Analysis N-methyl-2-pyrrolidone
Enforcement Discretion
Analytical Methods
Persons using assistive technology may not be able to fully access information in these methods. For assistance, please email AskCVM@fda.hhs.gov or call 240-402-7002.
- Quantitative Procedure for Residues of Albendazole in Cattle Liver
- Determination of Amprolium in Eggs and Meat and Meat Products of Chickens
- Determination of Apramycin in Swine Tissue
- Determination of Carbadox (as Quinoxaline-2-Carboxylic [QCA]) Residues in Swine Liver and Muscle Tissues After Drug Withdrawal
- Determinative and Confirmatory Procedures for the Assay of Fenbendazole Sulfone in Chicken Egg using LC-MS/MS
- Determinative and Confirmatory Procedures for Fenbendazole Sulfone in Liver Tissues of Broiler Chicken Using LC-MS/MS, Version 6.0
- Determinative and Confirmatory Procedures for the Detection of Fenbendazole in Liver Tissues of Swine Using LC-MS/MS v. 6.0
- Determinative and Confirmatory Procedures for the Analysis of Fenbendazole Sulfone in Turkey Liver Tissue Using LC-MS/MS, Version 9.0
- Determination and Confirmation of Lubabegron in Bovine Liver Tissue by LC-MS/MS
- Determination and Confirmation Analysis of Lufenuron Residues in Salmon and Trout Tissue by Liquid Chromatography-Tandem Mass Spectrometry Atmospheric Pressure Chemical Ionization (LC-MS/MS APCI)
- Determinative and Confirmatory Procedures for the Analysis of Oxfendazole in Cattle Milk Using LC-MS/MS, Version 6
Compliance & Enforcement
- Warning Letters
- Advisory Action Letters
- Medicated Feeds
- Ruminant Feed Inspections
- CVM Letter to Feed and Feed Ingredient Manufacturers
- Establishment Inspection Report - Gambol Pet Products Co.
- Establishment Inspection Report - Jinan Uniwell Pet Food Co., Ltd.
- Establishment Inspection Report - Shandong Honva Food Co. Ltd.
- Establishment Inspection Report - Shandong Petswell Food Co. Ltd.
- 2010 Jerky Complaints
- 2011 Jerky Complaints
- 2012-January 2013 Jerky Complaints
- February 2013-September 2013 Jerky Complaints
- September 2013-May 2014 Jerky Complaints
- May-September 2014 Jerky Complaints
- Establishment Inspection Report - Yantai Aska Food
- Yantai Aska Foods 483
- Establishment Inspection Report - Acidchem
- Letter to Kasel Associates Industries, Inc. - Notification of Opportunity to Initiate a Voluntary Recall
Safety & Health
- Adverse Event Reports for Animal Drugs and Devices
- Veterinary Medicine Advisory Committee
- Target Animal Safety Review Memorandum: Trace Metal Analysis of Commercial Pet Food for Toxic Metals
- Food and Drug Administration/Center for Veterinary Medicine Report on the Risk from Pentobarbital in Dog Food
CVM's researchers have concluded that the low levels of exposure to pentobarbital that dogs might receive through pet food is unlikely to cause them any adverse health effects. - FDA Records Related to Nestle Purina Beneful Dry Dog Food
- Response for Request for Adverse Event Reports Received for Afoxolaner, Fluralaner, Lotilaner, and Sarolaner
- FDA CVM Comprehensive ADE Report Listing for Afoxolaner (Nexgard): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Fluralaner (Bravecto): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Lotilaner (Credelio): 9/4/13 - 7/31/18
- FDA CVM Comprehensive ADE Report Listing for Sarolaner (Simparica): 9/4/13 - 7/31/18
- Dr. Steven Solomon Presentation -- NGFA‐PFI FEED AND PET FOOD JOINT CONFERENCE -- September 2018
- AFIA Salmonella Webcast PowerPoint – April 2010
Canine Dilated Cardiomyopathy
- FDA CVM FOIA-2019-1704-001147 - FDA CVM FOIA-2019-1704-001161
- FDA CVM FOIA 2019-1704-001191 - FDA CVM FOIA 2019-1704-003926
- FDA CVM FOIA 2019-1704-001255 - FDA CVM FOIA 2019-1704-007577
- FDA-CVM-FOIA-2019-1704-001174 - FDA-CVM-FOIA-2019-1704-006003
- FDA-CVM-FOIA-2019-1704-006219 - FDA-CVM-FOIA-2019-1704-007609
- FDA-CVM-FOIA-2019-1704-001150 - FDA-CVM-FOIA-2019-1704-003878
- FDA-CVM-FOIA-2019-1704-003881 - FDA-CVM-FOIA-2019-1704-007572
- FDA-CVM-FOIA-2019-1704-001220 - FDA-CVM-FOIA-2019-1704-003375
- FDA-CVM-FOIA-2019-1704-003383 - FDA-CVM-FOIA-2019-1704-005966
- FDA-CVM-FOIA-2019-1704-005970 - FDA-CVM-FOIA-2019-1704-007592
- FDA-CVM-FOIA-2019-1704-001611 - FDA-CVM-FOIA-2019-1704-008063
- FDA-CVM-FOIA-2019-1704-008064 - FDA-CVM-FOIA-2019-1704-015075
- FDA-CVM-FOIA-2019-1704-001611 - FDA-CVM-FOIA-2019-1704-009511
- FDA-CVM-FOIA-2019-1704-009522 - FDA-CVM-FOIA-2019-1704-011552
- FDA-CVM-FOIA-2019-1704-011559 - FDA-CVM-FOIA-2019-1704-013713
- FDA-CVM-FOIA-2019-1704-013716 - FDA-CVM-FOIA-2019-1704-014895
- FDA-CVM-FOIA-2019-1704-014896 - FDA-CVM-FOIA-2019-1704-015185
- FDA-CVM-FOIA-2019-1704-001355 - FDA-CVM-FOIA-2019-1704-010458
- FDA-CVM-FOIA-2019-1704-011203 - FDA-CVM-FOIA-2019-1704-012278
- FDA-CVM-FOIA-2019-1704-012279 - FDA-CVM-FOIA-2019-1704-014284
- FDA-CVM-FOIA-2019-1704-014285 - FDA-CVM-FOIA-2019-1704-015385
- FDA-CVM-FOIA-2019-1704-002503 - FDA-CVM-FOIA-2019-1704-002744
- FDA CVM FOIA-2019-1704-000001 - FDA CVM FOIA-2019-1704-000117
- FDA CVM FOIA-2019-1704-000118 - FDA CVM FOIA-2019-1704-000522
- FDA CVM FOIA-2019-1704-000523 - FDA CVM FOIA-2019-1704-000700
- FDA CVM FOIA-2019-1704-000701 - FDA CVM FOIA-2019-1704-001146
- FDA CVM FOIA-2019-1704-001162 - FDA CVM FOIA-2019-1704-005892
- FDA CVM FOIA-2019-1704-005921 - FDA CVM FOIA-2019-1704-010294
- FDA CVM FOIA-2019-1704-010297 - FDA CVM FOIA-2019-1704-011237
- FDA CVM FOIA-2019-1704-011507 - FDA CVM FOIA-2019-1704-013797
- FDA CVM FOIA-2019-1704-013878 - FDA CVM FOIA-2019-1704-015207
- FDA CVM FOIA-2019-1704-015208 - FDA CVM FOIA-2019-1704-015676
- FDA CVM FOIA-2019-1704-015677 - FDA CVM FOIA-2019-1704-016176
- FDA CVM FOIA-2019-1704-016177 - FDA CVM FOIA-2019-1704-016517
- FDA CVM FOIA-2019-1704-016518 - FDA CVM FOIA-2019-1704-016808
- FDA CVM FOIA-2019-1704-016809 - FDA CVM FOIA-2019-1704-017325
- FDA CVM FOIA-2019-1704-017326 - FDA CVM FOIA-2019-1704-017770
- FDA CVM FOIA-2019-1704-017771 - FDA CVM FOIA-2019-1704-018116
- FDA CVM FOIA-2019-1704-018117 - FDA CVM FOIA-2019-1704-018662
- FDA CVM FOIA-2019-1704-018663 - FDA CVM FOIA-2019-1704-019385
High Pressure Processing (HPP) – FOIA 2018-7843
- FDA-CVM-FOIA-Case-1-20-cv-00656-000002780 - FDA-CVM-FOIA-Case-1-20-cv-00656-000002784
- FDA-CVM-FOIA-Case-1-20-cv-00656-000004099
- FDA-CVM-FOIA-Case-1-20-cv-00656-000004100 - FDA-CVM-FOIA-Case-1-20-cv-00656-000004118
Adverse Event Reports
- Adverse Event Reports - May 1, 2010-May 1, 2011
- Adverse Event Reports - May 2, 2011-May 1, 2012
- Adverse Event Reports - May 2, 2012-May 1, 2013
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 1
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 2
- Adverse Event Reports - May 2, 2013-May 1, 2014 - Part 3
- Adverse Event Reports - May 2, 2014-May 1, 2015
- Adverse Event Reports - May 2, 2015-May 1, 2016
- Adverse Event Reports - May 2, 2016-May 1, 2017
- Adverse Event Reports - May 2, 2017-May 1, 2018
- Adverse Event Reports - May 2, 2018-May 1, 2019
- Adverse Event Reports - May 2, 2019-May 1, 2020
- Adverse Event Reports - May 2, 2020-May 1, 2021
- Adverse Event Reports - May 2, 2021-June 10, 2022
- Response for Request for Adverse Event Reports Received for Bedinvetmab (Librela) and Frunevetmab (Solensia)
- Summary of Purina Pet Food Adverse Event Reports (November 22, 2023 - April 15, 2024), FDA Actions and Findings